Cargando…

Fludarabine-Melphalan-Campath, Followed by Unmanipulated Peripheral-Blood Haematopoietic Stem Cells, Can Still Cure Lymphoma

BACKGROUND: The second decade of this millennium was characterized by a widespread availability of chimeric antigen receptor T-cell (CAR-T) therapies to treat relapsed and refractory lymphomas. As expected, the role and indication of allogeneic haematopoietic stem cell transplant (allo-HSCT) in the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Avenoso, Daniele, Alabdulwahab, Amal, Kenyon, Michelle, Mehra, Varun, Krishnamurthy, Pramila, Dazzi, Francesco, Leung, Ye Ting, Anteh, Sandra, Shah, Mili Naresh, Kuhnl, Andrea, Sanderson, Robin, Patten, Piers, Yallop, Deborah, Pagliuca, Antonio, Potter, Victoria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Università Cattolica del Sacro Cuore 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10332350/ https://www.ncbi.nlm.nih.gov/pubmed/37435036 http://dx.doi.org/10.4084/MJHID.2023.041

Ejemplares similares

P1288: UNMANIPULATED PERIPHERAL HAPLOIDENTICAL HAEMATOPOIETIC STEM CELL TRANSPLANT IS AN EFFECTIVE CONSOLIDATIVE STRATEGY FOR HIGH-RISK ACUTE MYELOID LEUKAEMIA AND MYELODYSPLASTIC SYNDROME
por: Serpenti, Fabio, et al.
Publicado: (2023)

Human Herpesvirus 6 Encephalitis Following Axicabtagene Ciloleucel Treatment for Refractory Diffuse Large B Cell Lymphoma
por: Shah, Mili, et al.
Publicado: (2021)

Relationship of iothalamate clearance and NRM in patients receiving fludarabine and melphalan reduced-intensity conditioning
por: Kutzke, Jade L., et al.
Publicado: (2022)

Comparison of fludarabine–melphalan and fludarabine–treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation—a registry study on behalf of the EBMT Acute Leukemia Working Party
por: Duque-Afonso, Jesus, et al.
Publicado: (2022)

The evolving role of alemtuzumab (Campath-1H) in renal transplantation
por: Pham, Phuong-Thu T, et al.
Publicado: (2009)

Reduced Intensity Allogeneic Hematopoietic Cell Transplantation using Fludarabine-Melphalan conditioning for Treatment of Mature T-cell Lymphomas
por: Delioukina, Maria, et al.
Publicado: (2011)

Comparison of graft versus host disease with three different alemtuzumab schedules in unrelated donor fludarabine and melphalan allografts
por: Green, Kile, et al.
Publicado: (2017)

P1169: ELEVATED CRP AT INFUSION OF AXICABTAGENE CILOLEUCEL PREDICTS HIGH-GRADE CAR-T TOXICITY AND OUTPERFORMS MORE COMPLEX SCORES
por: Boyle, S., et al.
Publicado: (2022)

Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis
por: Dalakas, Marinos C., et al.
Publicado: (2009)

Comparison of reduced-toxicity conditioning protocols using fludarabine, melphalan combined with thiotepa or carmustine in allogeneic hematopoietic cell transplantation
por: Duque-Afonso, Jesús, et al.
Publicado: (2020)

A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT
por: Tran, Misha C., et al.
Publicado: (2022)

Unmanipulated haploidentical transplantation for adult patients with hematological malignancies
por: Ruggeri, Annalisa, et al.
Publicado: (2019)

Comparable safety profile of BeEAM (bendamustine, etoposide, cytarabine, melphalan) and BEAM (carmustine, etoposide, cytarabine, melphalan) as conditioning before autologous haematopoietic cell transplantation
por: Frankiewicz, Andrzej, et al.
Publicado: (2018)

Mixed T cell lineage chimerism in acute leukemia/MDS using pre-emptive donor lymphocyte infusion strategy—Is it prognostic?—a single-center retrospective study
por: Sheth, Vipul, et al.
Publicado: (2021)

Unusual CD34 positivity in acute myeloid leukaemia with myelodysplasia‐related changes with megakaryoblastic differentiation
por: Avenoso, Daniele, et al.
Publicado: (2021)

P1318: THE IMPACT OF MELPHALAN DOSING IN COMBINATION WITH FLUDARABINE IN CLINICAL OUTCOMES OF PATIENTS WITH ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES RECEIVING ALLO-HCT
por: Albanyan, O., et al.
Publicado: (2022)

PB2193: IS HYPERHYDRATION NECESSARY FOR HIGH DOSE MELPHALAN CONDITIONING REGIMEN IN AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANTATION?
por: Mora Argumánez, M., et al.
Publicado: (2022)

The risk of early and late cytomegalovirus DNAemia associated with Campath use in stem cell transplant recipients
por: Buyck, Hubertus C, et al.
Publicado: (2009)

BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Versus BEAM (Carmustine, Etoposide, Cytarabine, Melphalan) as Conditioning Regimen Before Autologous Haematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis
por: Wu, Ran, et al.
Publicado: (2023)

The Effects of CAMPATH-1H on Cell Viability Do Not Correlate to the CD52 Density on the Cell Surface
por: Lee, Fuiyee, et al.
Publicado: (2014)

Population Pharmacokinetics of Alemtuzumab (Campath) in Pediatric Hematopoietic Cell Transplantation: Towards Individualized Dosing to Improve Outcome
por: Admiraal, Rick, et al.
Publicado: (2019)

Innovative Platforms for Haploidentical Stem Cell Transplantation: The Role of Unmanipulated Donor Graft
por: Ciceri, Fabio, et al.
Publicado: (2011)

Granulocyte Colony-Stimulating Factor-Primed Unmanipulated Haploidentical Blood and Marrow Transplantation
por: Chang, Ying-Jun, et al.
Publicado: (2019)

Targeting of Natural Killer Cells by Rabbit Antithymocyte Globulin and Campath-1H: Similar Effects Independent of Specificity
por: Stauch, Diana, et al.
Publicado: (2009)

Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (3C) study: background, rationale, and study protocol
por: Haynes, Richard, et al.
Publicado: (2013)

Comparison of Subcutaneous versus Intravenous Alemtuzumab for Graft-versus-Host Disease Prophylaxis with Fludarabine/Melphalan–Based Conditioning in Matched Unrelated Donor Allogeneic Stem Cell Transplantation
por: Patel, Khilna, et al.
Publicado: (2016)

Fludarabine as a cost-effective adjuvant to enhance engraftment of human normal and malignant hematopoiesis in immunodeficient mice
por: Pievani, A., et al.
Publicado: (2018)

CD34-selected versus unmanipulated autologous haematopoietic stem cell transplantation in the treatment of severe systemic sclerosis: a post hoc analysis of a phase I/II clinical trial conducted in Japan
por: Ayano, Masahiro, et al.
Publicado: (2019)

Combination of 9-aminoacridine with Campath-1H provides effective therapy for a murine model of adult T-cell leukemia
por: Ju, Wei, et al.
Publicado: (2014)

Campath, calcineurin inhibitor reduction, and chronic allograft nephropathy (the 3C Study) – results of a randomized controlled clinical trial
por: Haynes, Richard, et al.
Publicado: (2018)

Early FDG-PET response predicts CAR-T failure in large B-cell lymphoma
por: Kuhnl, Andrea, et al.
Publicado: (2022)

CD34(+) cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignancies
por: Holtan, S G, et al.
Publicado: (2010)

Neurological illness following treatment with fludarabine.
por: Johnson, P. W., et al.
Publicado: (1994)

[(18)F]-Fludarabine for Hematological Malignancies
por: Barré, Louisa, et al.
Publicado: (2019)

Lymphoid blast crisis after prolonged treatment‐free remission in chronic myeloid leukaemia after tyrosine kinase inhibitor de‐escalation during the COVID‐19 pandemic
por: Avenoso, Daniele, et al.
Publicado: (2021)

Leukemia relapse following unmanipulated haploidentical transplantation: a risk factor analysis on behalf of the ALWP of the EBMT
por: Piemontese, Simona, et al.
Publicado: (2019)

Immunological and Clinical Impact of Manipulated and Unmanipulated DLI after Allogeneic Stem Cell Transplantation of AML Patients
por: Greiner, Jochen, et al.
Publicado: (2019)

ALL-RIC trial protocol: a comparison of reduced dose total body irradiation (TBI) and cyclophosphamide with fludarabine and melphalan reduced intensity conditioning in adults with acute lymphoblastic leukaemia (ALL) in complete remission
por: Marks, David I, et al.
Publicado: (2023)

Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission
por: Saraceni, Francesco, et al.
Publicado: (2017)

A comparison between allogeneic stem cell transplantation from unmanipulated haploidentical and unrelated donors in acute leukemia
por: Piemontese, Simona, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_4a6tlhqdjrdh0cj60m5dh6nakj